The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
Following the receipt of an update from the company that market nivolumab, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this, the scoping exercise has been cancelled and will be rearranged at a later date. Please accept our apologies for any inconvenience.
If you have any comments or concerns, please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk).